Synthetic small molecule tyrosine kinase inhibitors (TKIs) have also been developed for the treatment of HER2+ BC: for example, lapatinib, a reversible first generation TKI, which prevents phosphorylation and activation of both HER2 and EGFR (Gril et al., 2008; Kim et al., 2009; Yuan et al., 2022), has been proven to be clinically effective against the HER2+ BC (Bilancia et al., 2007). The gene discussed is ERBB2; the disease is breast cancer.